Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Japanese patients with prurigo nodularis and moderate to severe pruritus
jRCT2011200017Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nemolizumab in prurigo nodularis (PN) (3 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Percent change from baseline of weekly average in Peak Pruritus Numeric Rating Scale (PP-NRS) at Week 16. Started Dec 2020; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2011200017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011200017.